

Barcelona, June 11<sup>th</sup> 2021

## **OTHER RELEVANT INFORMATION**

### **Almirall appoints Dr. Karl Ziegelbauer as the new Chief Scientific Officer**

In accordance with Securities Markets Law approved Almirall, S.A. (“Almirall”) announce the following:

The Board of Directors have approved the appointment of Mr. Karl Ziegelbauer as Chief Scientific Officer effective July 1, 2021.

Dr. Ziegelbauer joins Almirall from Bayer Pharmaceuticals, where he most recently served as Senior Vice President and Head of Open Innovation & Digital Technologies. Almirall’s new CSO is a recognized industry leader and he brings with him three decades of leadership experience in drug discovery and early clinical development in international markets such as Germany, Japan and the United States. He has developed most of his career at Bayer Pharmaceuticals and he has been assuming positions of increasing responsibility holding Senior Vice President roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives and immunology/inflammation.

Yours sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)